Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
46 shown of 2,399 total abstracts
  1. Abstract 66162026-09-02 · 14:00 CT · Arie Crown Theater
    KEYNOTE-694: Keytruda (pembrolizumab) adjuvant in RCC
    M.C. Garassino, J. Brahmer, R. Herbst · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 66692026-09-01 · 19:45 CT · S100A
    CheckMate-285: Opdivo (nivolumab) 3L+ in RCC
    M. Reck, F. Andre · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 66532026-09-05 · 18:30 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M. Krop, J. Brahmer · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 68472026-09-05 · 18:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-45 study)
    P. Schmid, S. Modi · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 61422026-09-05 · 19:45 CT · Hall B1
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-587
    J. Brahmer, M. Reck, G. Curigliano, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 66772026-09-05 · 14:00 CT · S100A
    Quality of life outcomes with Keytruda in patients with RCC
    M.C. Garassino, H. Rugo · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 61312026-09-05 · 19:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-470
    H. Rugo, M. Krop, S. Antonia, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 69082026-09-04 · 18:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-609 study)
    T. Mok, J. Brahmer, S. Peters, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 67882026-09-04 · 13:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-211
    S. Peters, S. Modi · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 69002026-09-02 · 13:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-195 study)
    J. Cortes, N. Rizvi, M. Reck, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 60162026-09-02 · 16:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-910
    S. Modi, J. Brahmer · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 66342026-09-03 · 20:15 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    M.C. Garassino, C. Robert, S. Antonia, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 64882026-09-02 · 19:30 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-456 study)
    S. Tolaney, C. Saura, S. Peters · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 69022026-09-04 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-332 study)
    T. Mok, S. Peters, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 67782026-09-03 · 20:15 CT · E450
    Quality of life outcomes with Opdivo in patients with RCC
    R. Herbst, P. Schmid, H. Borghaei · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 68462026-09-02 · 15:15 CT · Hall B1
    CheckMate-319: Opdivo (nivolumab) 1L in RCC
    A. Spira, G. Curigliano, S. Modi, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 68802026-09-03 · 15:00 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-394
    L. Paz-Ares, A. Spira, S. Antonia · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 60082026-09-05 · 19:15 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-94 study)
    S. Peters, F. Andre, P. Schmid · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 69092026-09-03 · 19:30 CT · Arie Crown Theater
    KEYNOTE-415: Keytruda (pembrolizumab) 3L+ in RCC
    P. Schmid, N. Rizvi, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 64092026-09-04 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-914 study)
    H. Rugo, C. Saura · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 68902026-09-02 · 16:00 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-16
    M. Krop, S. Peters · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 67262026-09-01 · 18:45 CT · E450
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-472
    M. Reck, M.C. Garassino, G. Curigliano, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  23. Abstract 66522026-09-03 · 21:00 CT · S406
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-896
    R. Herbst, J. Cortes, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract 67302026-09-02 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-970
    S. Tolaney, J. Brahmer, F. Andre, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  25. Abstract 63632026-09-01 · 16:00 CT · S406
    KEYNOTE-204: Keytruda (pembrolizumab) 3L+ in RCC
    J. Brahmer, C. Robert, R. Herbst, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  26. Abstract 62442026-09-05 · 18:00 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-610
    M. Krop, S. Peters, M.C. Garassino · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  27. Abstract 61982026-09-01 · 19:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-168
    C. Robert, S. Antonia, J. Cortes · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 68632026-09-01 · 13:45 CT · S100A
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-331
    C. Robert, S. Antonia, T. Mok, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  29. Abstract 66792026-09-03 · 18:15 CT · Hall B1
    KEYNOTE-705: Keytruda (pembrolizumab) neoadjuvant in RCC
    S. Antonia, J. Cortes, C. Saura, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract 62022026-09-02 · 21:30 CT · Hall B1
    KEYNOTE-213: Keytruda (pembrolizumab) 3L+ in RCC
    E. Winer, M. Krop, M. Reck · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 63312026-09-02 · 13:15 CT · S100A
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-852
    E. Winer, A. Spira, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 69372026-09-02 · 21:00 CT · S100A
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-826
    J. Cortes, C. Robert, S. Peters, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 65302026-09-04 · 21:30 CT · E450
    CheckMate-542: Opdivo (nivolumab) 3L+ in RCC
    S. Modi, M. Krop, F. Andre, et al. · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 60122026-09-05 · 15:15 CT · S100A
    KEYNOTE-285: Keytruda (pembrolizumab) maintenance in RCC
    C. Saura, F. Andre, C. Robert, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 63132026-09-03 · 20:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-657
    L. Paz-Ares, T. Mok, J. Cortes · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 67152026-09-01 · 20:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-449
    A. Spira, S. Antonia, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 61352026-09-01 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-41 study)
    S. Antonia, T. Mok · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  38. Abstract 68712026-09-01 · 21:45 CT · Arie Crown Theater
    CheckMate-200: Opdivo (nivolumab) 3L+ in RCC
    H. Rugo, T. Mok · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract 66572026-09-05 · 18:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-992 study)
    E. Winer, M.C. Garassino, J. Cortes, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 65062026-09-03 · 14:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-480
    S. Modi, J. Cortes, M.C. Garassino, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract 60742026-09-04 · 18:45 CT · S406
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-874
    A. Spira, J. Brahmer, S. Peters · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 67692026-09-05 · 13:00 CT · E450
    CheckMate-421: Opdivo (nivolumab) adjuvant in RCC
    J. Cortes, A. Spira, G. Curigliano · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  43. Abstract 60412026-09-01 · 15:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-231
    N. Rizvi, J. Brahmer, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  44. Abstract 64642026-09-01 · 19:00 CT · E450
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-964
    G. Curigliano, S. Tolaney, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract 67242026-09-05 · 20:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-648 study)
    S. Antonia, A. Spira · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  46. Abstract 63622026-09-04 · 13:00 CT · S406
    Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-550
    F. Andre, C. Robert, R. Herbst, et al. · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.